Levels of Circulating TIMP-2 and MMP2-TIMP2 Complex Are Decreased in Squamous Cervical Carcinoma by Anne, Talvensaari-Mattila & Taina, Turpeenniemi-Hujanen
Hindawi Publishing Corporation
Obstetrics and Gynecology International
Volume 2010, Article ID 179351, 3 pages
doi:10.1155/2010/179351
Research Article
Levels of CirculatingTIMP-2 and MMP2-TIMP2 ComplexAre
Decreased in SquamousCervical Carcinoma
Talvensaari-MattilaAnne1 andTurpeenniemi-HujanenTaina2
1Department of Obstetrics and Gynecology, Oulu University Hospital, University of Oulu, P.O. Box 24, 90029 OYS Oulu, Finland
2Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, P.O. Box 24, 90029 OYS Oulu, Finland
Correspondence should be addressed to Talvensaari-Mattila Anne, anne.talvensaari-mattila@oulu.ﬁ
Received 21 February 2010; Accepted 13 May 2010
Academic Editor: William T. Creasman
Copyright © 2010 T.-M. Anne and T.-H. Taina.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. The role of matrix metalloproteinase-2 and -9 (MMP-2, MMP-9) in matrix degradation and metastasis has been
described in various tumors. Their action is inhibited by their natural tissue inhibitor molecules TIMP-1 and -2. Methods.T h e
study population consisted of 12 squamous cervical carcinoma patients and 27 healthy volunteer control patients. MMP-9, MMP-
2-TIMP-2complex,TIMP-1,andTIMP-2wereanalyzedfromserumsamplesusingenzyme-linkedimmunoassay(ELISA).Results.
The mean levels of serum TIMP-2 and of MMP-2-TIMP-2 complex were higher in healthy controls compared to patients with
a malignant tumor. Serum TIMP-2 values decreased signiﬁcantly from healthy controls (median 323µg/l, range 305–342µg/l) to
malignant(median136µg/l,range120–151µg/l)squamouscervicalcarcinomapatients(P<. 000).Also,serumproMMP2-TIMP2
complex values decreased from control patients to squamous cervical carcinoma patients (P<. 006). Conclusion. This paper shows
that the levels of circulating TIMP-2 and that of MMP-2-TIMP-2 complex are lower in squamous cervical carcinoma patients than
in healthy women.
1.Introduction
Cervical cancer is the second most common malignant
disease among womenworldwide [1]. However, its incidence
and mortality rates have been decreasing in many highly
developed countries, for example, the Nordic countries,
mainly due to organized Pap smear screening [2].
Members of the matrix metalloproteinase (MMP) family
have the ability to degrade macromolecules of the extracellu-
lar matrix, and they are responsible for tumor invasion and
inﬁltration. They are a family of zinc and calcium-dependent
proteinases, and they are secreted in the proenzyme form
[3]. Besides their role in tumor invasion and metastasis,
MMPsareinvolvedinvariousphysiologicalconnectivetissue
remodeling processes, such as ovulation and wound healing
[4].
Matrix metalloproteinases form an enzyme family that
takes part in virtually all events of extracellular matrix
remodeling and turnover. Cancer cells capable of producing
these enzymes, especially of gelatinases MMP-2 and -9, have
been shown to have increased invasion potential in several
malignancies [5, 6]. Their action is inhibited by their natural
tissue inhibitor molecules TIMP-1 and -2.
There are no previous studies on circulating metal-
loproteinases and squamous cervical carcinoma. The aim
of this paper was to evaluate the levels of circulating
metalloproteinases and their inhibitors in squamous cervical
carcinoma patients and healthy women.
2.MaterialsandMethods
The patient material consisted of 12 early-stage (FIGO
stage IB and IIA) squamous cervical carcinoma patients
who underwent surgery at Oulu University Hospital during
the years from 1992 to 1995 and 27 healthy volunteer
control patients. The serum samples were collected by taking
venous blood samples from the patients at the time of the
primarysquamouscervicalcancerdiagnosispriortosurgery.2 Obstetrics and Gynecology International
Table 1: Serum levels of MMP-2-TIMP-2 complex, MMP-9, TIMP-1, and TIMP-2 in patients with squamous cervical cancer and in healthy
controls.
Serum marker Cervical cancer mean (range) Healthy controls mean (range) P-value1
MMP-2-TIMP-2 (µg/l) 514 (453–575) 625 (588–662) .006
MMP-9 (µg/l) 74 (40–108) 73 (59–87) .659
TIMP-1 (µg/l) 466 (422–511) 414 (383–443) .067
TIMP-2 (µg/l) 136 (120–151) 323 (305–342) .000
The results are expressed as mean (range).1 Wilcox
Thesampleswerecollectedinglasstubesthatdidnotcontain
any artiﬁcial coagulation activators. They were allowed to
coagulate, centrifuged at 3000rpm for 10 minutes, and the
nativeserumobtainedwasseparatedandfrozenat−20◦ until
used.
All patients with cervical carcinoma were treated with
preoperativeintracavitarybrachytherapy,followedbyradical
hysterectomy and lymph node dissection. The majority of
the patients received postoperative radiation. Additional
platinol-based chemotherapy was given if pelvic lymph
node metastases were found in the operation. The patients’
median age was 52 years, ranging from 31 to 80, at the
moment of diagnosis. The follow-up time for each patient
was 120 months at the minimum.
2.1. Assay for the Immunoreactive Proteins of MMP-2-TIMP-2
Complex, MMP-9, TIMP-1, and TIMP-2. The immunoreac-
tive proteins for MMP-2-TIMP-2 -complex, MMP-9, TIMP-
1, and TIMP-2 were assayed from the sera of the patients
with squamous cervical carcinoma and from that of healthy
volunteers using enzyme-linked immunoassay (ELISA). The
quantiﬁcation of the total protein of MMP-2-TIMP-2 com-
plex, MMP-9, TIMP-1, or TIMP-2 was performed using
standard protocols [7]. Brieﬂy, the ELISAs were performed
on EIA/RIA 8-well stripes (Corning Incorporated, Corning,
New York, USA). A polyclonal antibody produced in chicken
against each of the analytes was used as a secondary anti-
body. O-phenylenediamine dihydrochloride (OPD) (Sigma,
Steinheim, Germany) was used to visualize the peroxidase
label. Color formation was measured on 450nm (Anthos
2001 microplate reader), and calculations were done using
a Windows-based control and evaluation software for Rosys
Anthos microplate readers(Anthos labtecinstruments, Wals,
Austria).
The monoclonal antibody against MMP-2-TIMP-2 rec-
ognizes the solube lMMP-2-TIMP-2 complex. The mono-
clonal antibody against MMP-9 (code Ge-213) recognizes
both free MMP-9 and that bound to its inhibitor TIMP-1.
The monoclonal antibody against TIMP-1 (code DB-102D1)
recognizesbothfreeTIMP-1andthatcomplexedwithMMP-
9. It does not cross-react with TIMP-2. The monoclonal
antibody against TIMP-2 (code T2-101) recognizes both free
TIMP-2 and that complexed with MMP-2.
Each sample was run in duplicate in order to minimize
intraassay variation. The absorbance values for standard
samples and the standard curves constructed for each assay
were compared and used to minimize interassay variation.
2.2. Statistical Analysis. Statistical analysis was performed
with SPSS (v. 11.5) for Windows (SPSS Inc, Chicago, Ill.
USA) software package. Wilcox test was used to investigate
the signiﬁcance of the diﬀerences between medians. A P-
value <. 05 was considered statistically signiﬁcant.
3. Results
The mean levels of serum TIMP-2 and MMP-2-TIMP-2
complex were higher in the healthy controls compared to
those with a malignant tumor (Table 1). For the MMP-9
and TIMP-1, no signiﬁcant diﬀerences were found between
patients’ and controls’ concentrations.
Serum TIMP-2 values decreased signiﬁcantly from
healthy controls (mean 323µg/l, range 305–342µg/l) to
malignant (mean 136µg/l, range 120–151µg/l) squamous
cervical carcinoma patients (P<. 000).
Serum proMMP2-TIMP2 complex values decreased
from control patients (mean 625µg/l, range 588–662µg/l) to
malignant (mean 514µg/l, range 453–575µg/l) to squamous
cervical carcinoma patients (P<. 006).
4. Discussion
This paper shows for the ﬁrst time that the levels of
circulating TIMP-2 and the MMP-2-TIMP-2 complex are
lower in squamous cervical cancer patients than in healthy
women. Previously Ylisirni¨ o et al. [8] found that the TIMP-
2 and the MMP-2/TIMP-2 complex levels were lower in
lung cancer than in the sera of the control subjects. Also
in colorectal cancer, the serum levels of the MMP-2-TIMP-
2 complex are found to be lower than in healthy controls
[9]. Paula et al. [10] found that breast cancer patients had
signiﬁcantly lower TIMP-2 levels than did healthy controls.
We found in this study that squamous cervical cancer
patients had signiﬁcantly lower TIMP-2 levels compared to
healthy controls. In squamous cervical cancer, no evidence
currently exists showing that TIMP-2 could be prognostic
when measured in peripheral blood. However, the presence
of the disease might alter the balance of the proteolysis.
Low TIMP-2 levels in the blood of squamous cervical cancer
patients could indicate more activated MMP-2 and therefore
higher usage of TIMP-2, or alternatively, the lower levels
could be due to lower production of TIMP-2, leading to less
inhibition of MMP-2 activity.
For the proMMP2-TIMP2 complex, lower concentra-
tions are found in squamous cervical cancer patients. It hasObstetrics and Gynecology International 3
been shown that during aggregation, platelets release MMP-
2 in its latent form [11] as well as other components of the
proMMP2/MT1-MMP/TIMP-2 system [12].
Patients and controls did not have signiﬁcant diﬀerences
in their serum MMP-9 and TIMP-1 levels, although the
ranges for MMP-9 and TIMP-1 concentrations were wider in
cancer patients compared with healthy controls. This could
indicate the presence of a disturbance, such as cancer, that
could aﬀect the levels of the analytes.
Inconclusion,decreasedcirculatinglevelsofTIMP-2and
MMP2-TIMP2 complex are found in the serum samples of
squamous cervical carcinoma patients. Future studies will
determine the prognostic value of TIMP-2 and MMP2-
TIMP2 in squamous cervical carcinoma.
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